CD2AP

Summary

CD2AP (CD2 associated protein, HGNC:14258) is a protein-coding gene on chromosome 6p12.3, encoding CD2-associated protein (Q9Y5K6). Seems to act as an adapter protein between membrane proteins and the actin cytoskeleton.

This gene encodes a scaffolding molecule that regulates the actin cytoskeleton. The protein directly interacts with filamentous actin and a variety of cell membrane proteins through multiple actin binding sites, SH3 domains, and a proline-rich region containing binding sites for SH3 domains. The cytoplasmic protein localizes to membrane ruffles, lipid rafts, and the leading edges of cells. It is implicated in dynamic actin remodeling and membrane trafficking that occurs during receptor endocytosis and cytokinesis. Haploinsufficiency of this gene is implicated in susceptibility to glomerular disease.

Source: NCBI Gene 23607 — RefSeq curated summary.

At a glance

• Gene–disease (curated): focal segmental glomerulosclerosis 3, susceptibility to (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 22
• Clinical variants (ClinVar): 464 total — 9 pathogenic, 10 likely-pathogenic
• Phenotypes (HPO): 20
• Druggable target: yes
• MANE Select transcript: NM_012120

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14258
Approved symbol	CD2AP
Name	CD2 associated protein
Location	6p12.3
Locus type	gene with protein product
Status	Approved
Aliases	CMS
Ensembl gene	ENSG00000198087
Ensembl biotype	protein_coding
OMIM	604241
Entrez	23607

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 9 protein_coding, 2 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000359314, ENST00000463175, ENST00000477159, ENST00000479857, ENST00000486693, ENST00000865252, ENST00000865253, ENST00000865254, ENST00000931707, ENST00000931708, ENST00000931709, ENST00000960842, ENST00000960843

RefSeq mRNA: 1 — MANE Select: NM_012120 NM_012120

CCDS: CCDS34472

Canonical transcript exons

ENST00000359314 — 18 exons

Exon	Start	End
ENSE00000619362	47533602	47533755
ENSE00000755720	47503280	47503440
ENSE00001139019	47609123	47609304
ENSE00001139023	47607927	47608028
ENSE00001139029	47606165	47606277
ENSE00001139036	47599301	47599443
ENSE00001139043	47595861	47596026
ENSE00001139049	47582003	47582065
ENSE00001139061	47579385	47579489
ENSE00001139077	47576524	47576602
ENSE00001139085	47574064	47574251
ENSE00001139093	47554646	47554766
ENSE00001139103	47544606	47544706
ENSE00001176400	47612473	47612536
ENSE00001454693	47624186	47627263
ENSE00001516297	47477789	47478248
ENSE00003554329	47577009	47577103
ENSE00003629079	47580864	47580900

Expression profiles

Bgee: expression breadth ubiquitous, 275 present calls, max score 98.97.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.4497 / max 565.7377, expressed in 1811 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
68157	23.3049	1802
68161	4.2379	1458
68158	3.8935	1134
68166	0.6140	350
68160	0.5927	280
68159	0.3496	140
68167	0.3439	120
204018	0.1132	35

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	98.97	gold quality
esophagus squamous epithelium	UBERON:0006920	97.04	gold quality
colonic mucosa	UBERON:0000317	96.99	gold quality
mucosa of sigmoid colon	UBERON:0004993	96.88	gold quality
duodenum	UBERON:0002114	96.14	gold quality
rectum	UBERON:0001052	94.49	gold quality
renal glomerulus	UBERON:0000074	94.47	gold quality
amniotic fluid	UBERON:0000173	94.41	gold quality
metanephric glomerulus	UBERON:0004736	94.32	gold quality
oral cavity	UBERON:0000167	94.24	gold quality
germinal epithelium of ovary	UBERON:0001304	94.19	gold quality
caput epididymis	UBERON:0004358	94.12	gold quality
corpus epididymis	UBERON:0004359	93.99	gold quality
palpebral conjunctiva	UBERON:0001812	93.91	gold quality
epithelium of nasopharynx	UBERON:0001951	93.89	gold quality
bronchial epithelial cell	CL:0002328	93.23	gold quality
epithelium of esophagus	UBERON:0001976	92.94	gold quality
choroid plexus epithelium	UBERON:0003911	92.89	gold quality
islet of Langerhans	UBERON:0000006	92.82	gold quality
visceral pleura	UBERON:0002401	92.74	gold quality
calcaneal tendon	UBERON:0003701	92.39	gold quality
mucosa of transverse colon	UBERON:0004991	92.19	gold quality
nephron tubule	UBERON:0001231	92.02	gold quality
colonic epithelium	UBERON:0000397	91.72	gold quality
parietal pleura	UBERON:0002400	91.62	gold quality
upper leg skin	UBERON:0004262	91.61	gold quality
pleura	UBERON:0000977	91.56	gold quality
buccal mucosa cell	CL:0002336	91.50	gold quality
epithelium of bronchus	UBERON:0002031	91.35	gold quality
seminal vesicle	UBERON:0000998	91.15	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	29.40
E-CURD-112	yes	14.47
E-CURD-122	yes	13.54
E-CURD-114	yes	9.70
E-ANND-3	yes	9.02

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CREB1, E2F1, FOS, JUND, LMX1B, SP1, SP3

miRNA regulators (miRDB)

242 targeting CD2AP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819

Literature-anchored findings (GeneRIF, showing 40)

• PSTPIP1 acts downstream of CD2/CD2AP to link CD2 engagement to the WASp-evoked actin polymerization required for synapse formation and T cell activation. (PMID:12530983)
• cortactin links receptor endocytosis to actin polymerization by binding both CD2AP and the Arp2/3 complex, which may facilitate the trafficking of internalized growth factor receptors (PMID:12672817)
• Cd2 antigen is linked to CAPZ via this protein and CIN85 (PMID:12690097)
• two patients with focal segmental glomerulosclerosis had a mutation predicted to ablate expression of one CD2AP allele, implicating CD2AP as a determinant of human susceptibility to glomerular disease (PMID:12764198)
• exposure to normal and non-nephrotic human plasma leads to a concentration of nephrin, podocin, CD2AP, and actin at the cell surface in podocytes (PMID:15659563)
• CD2AP is involved in cytokinesis. (PMID:15800069)
• CD2AP has a role in the regulation of the actin cytoskeleton (PMID:16707503)
• CFBP is a novel tyrosine-phosphorylated protein that might function as a regulator of CIN85/CD2AP (PMID:16895919)
• structures support the notion that, despite clear differences in the interaction surface, both Cbl-b and CD2 can mediate multimerization of N-terminal CMS SH3 domains (PMID:17020880)
• This work indicates the solution structure of CMS_SH3_B bears the canonical beta-beta-beta-beta-alpha-beta fold and a new binding site in c-Cbl involved in its interaction with CMS, which probably contributes to the clustering of CMS. (PMID:17188587)
• CIN85 is expressed as multiple isoforms that share the coiled-coil domain, suggesting that heterotypic interactions with CMS provides a mechanism to regulate CMS binding to F-actin and thus for modulating dynamic rearrangements of the cytoskeleton. (PMID:17606992)
• Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. (PMID:17713465)
• identified a polyproline-arginine sequence in the pTalpha cytoplasmic tail that interacted in vitro with SH3 domains of the CIN85/CMS family of adaptors, and mediated the recruitment of multiprotein complexes involving all (CMS, CIN85, and CD2BP3) members (PMID:17823309)
• that ALIX and TSG101/ESCRT-I also bind a series of proteins involved in cytokinesis, including CEP55, CD2AP, ROCK1, and IQGAP1. (PMID:17853893)
• The three-dimensional structure of CD2AP SH3-C contains all the features that are typically found in other SH3 domains, including the general binding site for the recognition of polyproline sequences. (PMID:17922258)
• promotor activity in rental tubular epithelial cells is regulated by CREB and Sp1 (PMID:18396147)
• Sp1/Sp3 binding sites play a critical role in the CD2AP regulation. (PMID:18791326)
• CD2AP mutations modify the interaction with CD2 in lymphocytes and alter the composition of the renal slit diaphragm. (PMID:19131354)
• CD2AP, through facilitating conjugate formation and directed transport of lytic granules, plays an important role in NK cells killing. (PMID:19945749)
• The absence of mutations of CD2AP in this study suggests that there are other genetic causes of steroid-resistant nephrotic syndrome (PMID:19956976)
• Data identify CD2AP as a novel Rac1-associated adapter protein that participates in the regulation of epithelial cell-cell contact. (PMID:20404345)
• Coexpression of CIN85/Ruk(L) with CD2AP led to a decreased binding of CIN85/Ruk(L) to nephrin and podocin, which indicates a functional competition between CD2AP and CIN85/Ruk(L). (PMID:20457601)
• The authors report that CD2AP, an endocytosis-associated and cortactin-binding protein, is a novel and important component of enteropathogenic Escherichia coli pedestal formation that also utilizes Y474 phosphorylation of the bacterial Tir. (PMID:20515931)
• found independent evidence for association for Alzheimer’s disease susceptibility loci at EPHA1, CD33 and CD2AP (PMID:21460840)
• Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. (PMID:21460841)
• found that the N-terminal SH3 domain of both adaptor proteins CD2AP and CIN85 are the most stable SH3 domains that have been studied until now (PMID:21519904)
• The urinary mRNA profiles of synaptopodin, podocalyxin, CD2-AP, alpha-actin4, and podocin were found to increase with the progression of diabetic nephropathy. (PMID:21655212)
• identifies CD2AP as the gatekeeper of the podocyte TGF-beta response through its regulation of CatL expression and defines a molecular mechanism underlying proteinuric kidney disease (PMID:21911934)
• CD2AP is highly expressed in human plasmacytoid dendritic cells (DC) and positively regulates blood DC antigen 2 (BDCA2)/Fc fragment of IgE high affinity I receptor (FcepsilonR1gamma) signaling. (PMID:22706086)
• E2F1 up-regulates the human CD2AP promoter. (PMID:22880102)
• an FRS2beta-CIN85/CD2AP-Cbl axis for downregulation of ErbB2 may regulate ErbB2 protein levels in physiological and pathological settings (PMID:23279575)
• CD2AP gene variants may contribute to susceptibility to end-stage renal disease in patients with type 1 diabetes. (PMID:23681557)
• FSGS3/CD2AP has a role of barbed-end capping in junctional actin dynamics. (PMID:24322428)
• CD2AP rs9349407 polymorphism contributes to Alzheimer’s disease susceptibility. (PMID:25092125)
• we present the first demonstration that the purified SH3 domains of the CD2AP/Cin85 protein family are able to directly bind the p53 protein, and to discriminate between the two polymorphic variants P72R (PMID:25261582)
• CD2-Associated Protein affects Abeta levels and Abeta42/Abeta40 ratio in vitro (PMID:25887956)
• discovered novel interaction candidates for CD2AP and characterized subtle yet significant differences in the recognition preferences of its three SH3 domains for c-CBL, ALIX, and RIN3 (PMID:26296892)
• Study found a novel association of CD2AP with plasma homocysteine in participants with African ancestry and found a new variant in the candidate gene CBS associated with homocysteine (PMID:26519441)
• CD2AP expression in renal tubules may histologically associate with tissue hypoxia and reflected recovery from CsA-mediated renal injury in nephrotic syndrome patients. (PMID:26975192)
• data thus reveal a Golgi-traversing pathway for exosomal release of the cargo protein GPRC5B in which CD2AP facilitates the entry and LMAN2 impedes the exit of the flux, respectively. (PMID:27765817)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cd2ap	ENSDARG00000015224
mus_musculus	Cd2ap	ENSMUSG00000061665
rattus_norvegicus	Cd2ap	ENSRNOG00000011987
drosophila_melanogaster	cindr	FBGN0027598
caenorhabditis_elegans	cdap-2	WBGENE00021549

Paralogs (3): SH3KBP1 (ENSG00000147010), NOSTRIN (ENSG00000163072), SH3D21 (ENSG00000214193)

Protein

Protein identifiers

CD2-associated protein — Q9Y5K6 (reviewed: Q9Y5K6)

Alternative names: Adapter protein CMS, Cas ligand with multiple SH3 domains

All UniProt accessions (1): Q9Y5K6

UniProt curated annotations — full annotation on UniProt →

Function. Seems to act as an adapter protein between membrane proteins and the actin cytoskeleton. In collaboration with CBLC, modulates the rate of RET turnover and may act as regulatory checkpoint that limits the potency of GDNF on neuronal survival. Controls CBLC function, converting it from an inhibitor to a promoter of RET degradation. May play a role in receptor clustering and cytoskeletal polarity in the junction between T-cell and antigen-presenting cell. May anchor the podocyte slit diaphragm to the actin cytoskeleton in renal glomerolus. Also required for cytokinesis. Plays a role in epithelial cell junctions formation.

Subunit / interactions. Homodimer. Interacts with F-actin, PKD2, NPHS1 and NPHS2. Interacts with WTIP. Interacts with DDN; interaction is direct. Interacts (via SH3 2 domain) with CBL (via phosphorylated C-terminus). Interacts with BCAR1/p130Cas (via SH3 domain). Interacts with MVB12A and ARHGAP17. Interacts with ANLN, CD2 and CBLB. Interacts with PDCD6IP and TSG101. Interacts with RIN3. Interacts directly with RET (inactive) and CBLC; upon RET activation by GDNF suggested to dissociate from RET as CBLC:CD2AP complex (PubMed:10339567, PubMed:11067845, PubMed:15800069, PubMed:16678097, PubMed:16895919, PubMed:17020880, PubMed:17853893, PubMed:18753381, Ref.30). Interacts with CGNL1 and SH3BP1; probably part of a complex at cell junctions. Interacts with CAPZA1. (Microbial infection) Interacts (via SH3 domains) with Chikungunya virus non-structural protein 3 (via C-terminus); this interaction plays a role in initiation of viral replication.

Subcellular location. Cytoplasm. Cytoskeleton. Cell projection. Ruffle. Cell junction.

Tissue specificity. Widely expressed in fetal and adult tissues.

Post-translational modifications. Phosphorylated on tyrosine residues; probably by c-Abl, Fyn and c-Src.

Disease relevance. Focal segmental glomerulosclerosis 3 (FSGS3) [MIM:607832] A renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Domain organisation. The Pro-rich domain may mediate binding to SH3 domains. Potential homodimerization is mediated by the coiled coil domain.

RefSeq proteins (1): NP_036252* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001452	SH3_domain	Domain
IPR035775	CD2AP_SH3_1	Domain
IPR035776	CD2AP_SH_2	Domain
IPR035777	CD2AP_SH3_3	Domain
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR050384	Endophilin_SH3RF	Family

Pfam: PF00018, PF14604

UniProt features (46 total): modified residue 11, strand 10, compositionally biased region 5, region of interest 4, domain 3, short sequence motif 3, sequence variant 3, helix 3, cross-link 2, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

12 structures.

PDB	Method	Resolution (Å)
3U23	X-RAY DIFFRACTION	1.11
4X1V	X-RAY DIFFRACTION	1.58
4WCI	X-RAY DIFFRACTION	1.65
7DS6	X-RAY DIFFRACTION	1.69
2J6F	X-RAY DIFFRACTION	1.7
3AA6	X-RAY DIFFRACTION	1.9
7DS8	X-RAY DIFFRACTION	1.95
3LK4	X-RAY DIFFRACTION	1.99
2J6O	X-RAY DIFFRACTION	2.23
2J6K	X-RAY DIFFRACTION	2.77
2J7I	X-RAY DIFFRACTION	2.9
2FEI	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y5K6-F1	63.04	0.31

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (13): 67, 80, 86, 224, 458, 463, 469, 510, 514, 565, 582, 58, 523

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-373753	Nephrin family interactions
R-HSA-1500931	Cell-Cell communication

MSigDB gene sets: 594 (showing top): ATF_B, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_NEGATIVE_REGULATION_OF_NEURON_APOPTOTIC_PROCESS, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOBP_CARBOHYDRATE_TRANSPORT, GOBP_EPITHELIUM_DEVELOPMENT, FREAC2_01, GOBP_INFLAMMATORY_RESPONSE, GCANCTGNY_MYOD_Q6, AREB6_03, GOBP_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_GROWTH, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION

GO Biological Process (59): immunological synapse formation (GO:0001771), liver development (GO:0001889), endothelium development (GO:0003158), lipid metabolic process (GO:0006629), apoptotic process (GO:0006915), substrate-dependent cell migration, cell extension (GO:0006930), inflammatory response (GO:0006954), response to oxidative stress (GO:0006979), actin filament organization (GO:0007015), signal transduction (GO:0007165), cell population proliferation (GO:0008283), male gonad development (GO:0008584), protein secretion (GO:0009306), response to wounding (GO:0009611), response to virus (GO:0009615), cell migration (GO:0016477), actin filament polymerization (GO:0030041), protein catabolic process (GO:0030163), Rab protein signal transduction (GO:0032482), response to insulin (GO:0032868), transforming growth factor beta1 production (GO:0032905), negative regulation of transforming growth factor beta1 production (GO:0032911), regulation of actin cytoskeleton organization (GO:0032956), maintenance of blood-brain barrier (GO:0035633), nerve growth factor signaling pathway (GO:0038180), phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0043491), negative regulation of neuron apoptotic process (GO:0043524), cell-cell adhesion mediated by cadherin (GO:0044331), cell-cell junction organization (GO:0045216), obsolete D-glucose import (GO:0046323), filopodium assembly (GO:0046847), neurotrophin TRK receptor signaling pathway (GO:0048011), regulation of synaptic plasticity (GO:0048167), lymph node development (GO:0048535), collateral sprouting (GO:0048668), positive regulation of protein secretion (GO:0050714), synapse organization (GO:0050808), T cell receptor signaling pathway (GO:0050852), negative regulation of small GTPase mediated signal transduction (GO:0051058), protein heterooligomerization (GO:0051291)

GO Molecular Function (9): structural constituent of cytoskeleton (GO:0005200), SH3 domain binding (GO:0017124), clathrin binding (GO:0030276), phosphatidylinositol 3-kinase regulatory subunit binding (GO:0036312), identical protein binding (GO:0042802), cadherin binding (GO:0045296), actin filament binding (GO:0051015), actin binding (GO:0003779), protein binding (GO:0005515)

GO Cellular Component (27): fibrillar center (GO:0001650), ruffle (GO:0001726), podosome (GO:0002102), nuclear envelope lumen (GO:0005641), cytoplasm (GO:0005737), late endosome (GO:0005770), plasma membrane (GO:0005886), actin cytoskeleton (GO:0015629), axon (GO:0030424), dendrite (GO:0030425), growth cone (GO:0030426), cell leading edge (GO:0031252), neuromuscular junction (GO:0031594), filamentous actin (GO:0031941), vesicle (GO:0031982), trans-Golgi network membrane (GO:0032588), centriolar satellite (GO:0034451), slit diaphragm (GO:0036057), extracellular exosome (GO:0070062), cytoskeleton (GO:0005856), actin filament (GO:0005884), cell-cell junction (GO:0005911), protein-containing complex (GO:0032991), cell projection (GO:0042995), neuron projection (GO:0043005), anchoring junction (GO:0070161), cell periphery (GO:0071944)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Cell-Cell communication	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
response to stress	2
cellular process	2
cytoskeleton	2
protein binding	2
neuron projection	2
cell-cell recognition	1
lymphocyte activation	1
gland development	1
hepaticobiliary system development	1
epithelium development	1
primary metabolic process	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
substrate-dependent cell migration	1
plasma membrane bounded cell projection assembly	1
defense response	1
actin cytoskeleton organization	1
supramolecular fiber organization	1
cell communication	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
gonad development	1
development of primary male sexual characteristics	1
protein transport	1
secretion by cell	1
establishment of protein localization to extracellular region	1
protein localization to extracellular region	1
response to other organism	1
cell motility	1
actin polymerization or depolymerization	1
protein polymerization	1
macromolecule catabolic process	1
protein metabolic process	1
small GTPase-mediated signal transduction	1
response to peptide hormone	1
structural molecule activity	1
cytoskeleton organization	1

Protein interactions and networks

STRING

1904 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD2AP	NPHS1	O60500	999
CD2AP	NPHS2	Q9NP85	999
CD2AP	KIRREL1	Q96J84	990
CD2AP	TJP1	Q07157	982
CD2AP	SYNPO	Q8N3V7	962
CD2AP	CD2	P06729	948
CD2AP	ACTN4	O43707	939
CD2AP	CTTN	Q14247	933
CD2AP	INF2	Q27J81	925
CD2AP	PLCE1	Q9P212	913
CD2AP	CBL	P22681	910
CD2AP	HCLS1	P14317	904
CD2AP	TRPC6	Q9Y210	903
CD2AP	KIRREL3	Q8IZU9	900
CD2AP	ABCA7	Q8IZY2	883

IntAct

185 interactions, top by confidence:

A	B	Type	Score
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
SGF29	NDC80	psi-mi:“MI:0914”(association)	0.840
CD2	CD2AP	psi-mi:“MI:0915”(physical association)	0.800
CBL	CD2AP	psi-mi:“MI:0915”(physical association)	0.800
CD2AP	CBL	psi-mi:“MI:0914”(association)	0.800
CBL	CD2AP	psi-mi:“MI:0407”(direct interaction)	0.800
CD2AP	CBL	psi-mi:“MI:0915”(physical association)	0.800
CD2AP	CD2	psi-mi:“MI:0407”(direct interaction)	0.800
CD2	CD2AP	psi-mi:“MI:0407”(direct interaction)	0.800
INO80E	TFPT	psi-mi:“MI:0914”(association)	0.790
CAPZA1	CAPZB	psi-mi:“MI:0915”(physical association)	0.750
CAPZA1	CAPZB	psi-mi:“MI:0407”(direct interaction)	0.750
CBLB	CD2AP	psi-mi:“MI:0915”(physical association)	0.750
CD2AP	CBLB	psi-mi:“MI:0914”(association)	0.750
CBLB	CD2AP	psi-mi:“MI:0407”(direct interaction)	0.750
CD2AP	CBLB	psi-mi:“MI:0407”(direct interaction)	0.750

BioGRID (319): CD2AP (Affinity Capture-Western), CD2AP (Biochemical Activity), CD2AP (Affinity Capture-MS), CD2AP (Affinity Capture-MS), CD2AP (Affinity Capture-MS), CD2AP (Affinity Capture-MS), CD2AP (Co-crystal Structure), CD2AP (Co-crystal Structure), CD2AP (Reconstituted Complex), CD2 (Reconstituted Complex), CBLB (Reconstituted Complex), CD2AP (Co-fractionation), CD2AP (Co-fractionation), CD2AP (Co-fractionation), CD2AP (Co-fractionation)

ESM2 similar proteins: A6QP06, A7KAX9, F1LRS8, F1QIC4, G5EBZ8, O18195, O42287, O43432, O43491, O60237, O75167, O76337, O82171, O94519, O97902, P11171, P11434, P34416, P41110, P41993, P48820, Q09459, Q15811, Q1AAU6, Q501J7, Q52KW0, Q5HYK7, Q5M775, Q5RAU1, Q5RDE1, Q69ZW3, Q6NZJ6, Q801E2, Q8BG95, Q8IZ21, Q8R550, Q91X43, Q925Q9, Q96B97, Q9HCH5

Diamond homologs: A0JNJ1, A1CEK6, A1DFN5, A2QW93, A4RF61, A6QLK6, A7A261, F1LRS8, O35179, O35964, O43307, O74749, O75791, O75886, O88811, O89100, O93436, P02549, P07751, P09215, P09216, P10830, P13395, P16054, P16086, P16546, P23298, P24723, P28867, P29355, P32793, P34885, P38753, P43603, P53281, P62993, P62994, P70297, P87379, P97306

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
E2F1	“up-regulates quantity by expression”	CD2AP	“transcriptional regulation”
FAM83G	“up-regulates activity”	CD2AP	binding
CD2AP	“up-regulates quantity”	F-actin_assembly	binding
CD2AP	“up-regulates activity”	ACTB	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 159 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of KIT signaling	5	26.8×	7e-05
Regulation of signaling by CBL	6	26.6×	3e-05
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	6	19.1×	6e-05
Signaling by CSF1 (M-CSF) in myeloid cells	6	18.5×	6e-05
DAP12 signaling	5	16.4×	5e-04
Signaling by SCF-KIT	6	13.3×	3e-04
RHOQ GTPase cycle	6	9.7×	1e-03
Golgi-to-ER retrograde transport	8	9.5×	1e-04

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of epidermal growth factor receptor signaling pathway	5	26.6×	1e-03
B cell receptor signaling pathway	5	13.9×	8e-03
ephrin receptor signaling pathway	5	11.9×	9e-03
regulation of embryonic development	5	11.5×	9e-03
regulation of actin cytoskeleton organization	7	7.7×	8e-03
regulation of small GTPase mediated signal transduction	7	7.0×	9e-03
regulation of cell cycle	10	5.2×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

464 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	9
Likely pathogenic	10
Uncertain significance	245
Likely benign	88
Benign	56

Top pathogenic / likely-pathogenic (19)

Variant ID	HGVS	Classification
1179195	NM_012120.3(CD2AP):c.1742dup (p.Asn581fs)	Pathogenic
2052128	NM_012120.3(CD2AP):c.1386_1387del (p.Ser463fs)	Pathogenic
2425759	NC_000006.11:g.(?47471016)(47471176_?)del	Pathogenic
3246214	NC_000006.11:g.(?47564630)(47567630_?)del	Pathogenic
3639749	NM_012120.3(CD2AP):c.494del (p.Glu164_Leu165insTer)	Pathogenic
4734644	NM_012120.3(CD2AP):c.301del (p.Thr101fs)	Pathogenic
4771695	NM_012120.3(CD2AP):c.1742del (p.Asn581fs)	Pathogenic
522522	NM_012120.3(CD2AP):c.1045+1G>A	Pathogenic
5703	NM_012120.3(CD2AP):c.730-1_730delinsCT	Pathogenic
1179189	NM_012120.3(CD2AP):c.250C>T (p.Arg84Ter)	Likely pathogenic
2633510	NM_012120.3(CD2AP):c.1193_1196del (p.Ala398fs)	Likely pathogenic
3065595	NM_012120.3(CD2AP):c.30T>G (p.Tyr10Ter)	Likely pathogenic
3066210	NM_012120.3(CD2AP):c.1108+1G>T	Likely pathogenic
3593667	NM_012120.3(CD2AP):c.298C>T (p.Gln100Ter)	Likely pathogenic
3593683	NM_012120.3(CD2AP):c.865_868del (p.Thr289fs)	Likely pathogenic
3593685	NM_012120.3(CD2AP):c.865del (p.Thr289fs)	Likely pathogenic
4081232	NM_012120.3(CD2AP):c.720dup (p.Pro241fs)	Likely pathogenic
4292755	NM_012120.3(CD2AP):c.330_334del (p.Arg111fs)	Likely pathogenic
4845711	NM_012120.3(CD2AP):c.764del (p.Gln255fs)	Likely pathogenic

SpliceAI

4158 predictions. Top by Δscore:

Variant	Effect	Δscore
6:47503276:TTAG:T	acceptor_loss	1.0000
6:47503277:TAG:T	acceptor_loss	1.0000
6:47503278:A:AC	acceptor_loss	1.0000
6:47503278:A:AG	acceptor_gain	1.0000
6:47503278:AGTT:A	acceptor_gain	1.0000
6:47503279:G:GG	acceptor_gain	1.0000
6:47503279:GT:G	acceptor_gain	1.0000
6:47503279:GTT:G	acceptor_gain	1.0000
6:47503279:GTTG:G	acceptor_gain	1.0000
6:47503279:GTTGA:G	acceptor_gain	1.0000
6:47503436:TTAAG:T	donor_gain	1.0000
6:47503437:TAAG:T	donor_gain	1.0000
6:47503438:AAG:A	donor_gain	1.0000
6:47503439:AG:A	donor_gain	1.0000
6:47503439:AGGTA:A	donor_loss	1.0000
6:47503440:GG:G	donor_gain	1.0000
6:47503441:G:GG	donor_gain	1.0000
6:47503441:GTAA:G	donor_loss	1.0000
6:47526741:G:GG	donor_gain	1.0000
6:47531417:T:TA	acceptor_gain	1.0000
6:47531418:G:A	acceptor_gain	1.0000
6:47533597:T:TA	acceptor_gain	1.0000
6:47533597:TGTA:T	acceptor_loss	1.0000
6:47533597:TGTAG:T	acceptor_gain	1.0000
6:47533598:GTA:G	acceptor_loss	1.0000
6:47533598:GTAGG:G	acceptor_gain	1.0000
6:47533600:A:AC	acceptor_loss	1.0000
6:47533600:A:AG	acceptor_gain	1.0000
6:47533600:AG:A	acceptor_gain	1.0000
6:47533601:G:A	acceptor_gain	1.0000

AlphaMissense

4168 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:47503421:T:C	F49S	1.000
6:47503436:T:A	V54D	1.000
6:47503328:T:C	L18S	0.999
6:47503384:T:A	W37R	0.999
6:47503384:T:C	W37R	0.999
6:47503386:G:C	W37C	0.999
6:47503386:G:T	W37C	0.999
6:47503388:T:C	L38P	0.999
6:47503393:G:A	G40R	0.999
6:47503393:G:C	G40R	0.999
6:47503394:G:A	G40E	0.999
6:47503432:T:C	F53L	0.999
6:47503434:C:A	F53L	0.999
6:47503434:C:G	F53L	0.999
6:47544672:T:C	L129P	0.999
6:47554658:T:A	W145R	0.999
6:47554658:T:C	W145R	0.999
6:47554660:G:C	W145C	0.999
6:47554660:G:T	W145C	0.999
6:47554668:G:A	G148E	0.999
6:47554695:T:C	F157S	0.999
6:47579440:T:C	F320S	0.999
6:47606226:A:C	R493S	0.999
6:47606226:A:T	R493S	0.999
6:47503352:T:A	I26N	0.998
6:47503415:G:A	G47E	0.998
6:47503423:C:A	P50T	0.998
6:47503423:C:T	P50S	0.998
6:47503424:C:A	P50H	0.998
6:47544666:T:C	L127P	0.998

dbSNP variants (sampled 300 via entrez): RS1000017010 (6:47625642 T>C), RS1000021512 (6:47533096 A>G,T), RS1000067858 (6:47622677 A>T), RS1000071154 (6:47539722 G>A), RS1000073778 (6:47579938 A>G), RS1000085230 (6:47575886 A>C), RS1000096046 (6:47579138 G>A), RS1000101097 (6:47562496 T>A), RS1000113981 (6:47490637 T>C), RS1000116415 (6:47510321 C>A), RS1000121509 (6:47622447 C>A), RS1000130009 (6:47619084 T>G), RS1000131875 (6:47533860 C>T), RS1000182565 (6:47552847 C>G), RS1000196792 (6:47559830 G>A,T)

Disease associations

OMIM: gene MIM:604241 | disease phenotypes: MIM:607832, MIM:603278

GenCC curated gene-disease

Disease	Classification	Inheritance
focal segmental glomerulosclerosis 3, susceptibility to	Strong	Autosomal dominant
familial idiopathic steroid-resistant nephrotic syndrome	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (2)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
inherited focal segmental glomerulosclerosis	Moderate	AD
focal segmental glomerulosclerosis 3, susceptibility to	Definitive	AR

Mondo (6): focal segmental glomerulosclerosis 3, susceptibility to (MONDO:0011917), inherited focal segmental glomerulosclerosis (MONDO:0005363), focal segmental glomerulosclerosis (MONDO:0100313), prostate cancer (MONDO:0008315), kidney disorder (MONDO:0005240), familial idiopathic steroid-resistant nephrotic syndrome (MONDO:0019006)

Orphanet (2): Hereditary steroid-resistant nephrotic syndrome (Orphanet:656), Familial prostate cancer (Orphanet:1331)

HPO phenotypes

20 total (20 of 20 shown, HPO-id order):

HPO	Term
HP:0000083	Renal insufficiency
HP:0000093	Proteinuria
HP:0000097	Focal segmental glomerulosclerosis
HP:0000707	Abnormality of the nervous system
HP:0000737	Irritability
HP:0000790	Hematuria
HP:0000822	Hypertension
HP:0000969	Edema
HP:0001945	Fever
HP:0001967	Diffuse mesangial sclerosis
HP:0002027	Abdominal pain
HP:0002315	Headache
HP:0002586	Peritonitis
HP:0003073	Hypoalbuminemia
HP:0003774	Stage 5 chronic kidney disease
HP:0011947	Respiratory tract infection
HP:0012579	Minimal change glomerulonephritis
HP:0012622	Chronic kidney disease
HP:0031504	Foamy urine
HP:0100539	Periorbital edema

GWAS associations

22 associations (top):

Study	Trait	p-value
GCST001026_7	Alzheimer’s disease (late onset)	9.000000e-09
GCST002245_7	Alzheimer’s disease (late onset)	5.000000e-11
GCST002337_129	Amyotrophic lateral sclerosis (sporadic)	5.000000e-06
GCST003157_1	Plasma homocysteine levels	5.000000e-08
GCST004611_61	High light scatter reticulocyte count	7.000000e-18
GCST004612_22	High light scatter reticulocyte percentage of red cells	5.000000e-17
GCST004619_50	Reticulocyte fraction of red cells	2.000000e-11
GCST004621_103	Red cell distribution width	4.000000e-15
GCST004622_195	Reticulocyte count	7.000000e-12
GCST004628_83	Immature fraction of reticulocytes	1.000000e-17
GCST007319_30	Alzheimer’s disease (late onset)	7.000000e-08
GCST007319_5	Alzheimer’s disease (late onset)	5.000000e-09
GCST007320_1	Alzheimer’s disease or family history of Alzheimer’s disease	3.000000e-10
GCST007320_96	Alzheimer’s disease or family history of Alzheimer’s disease	1.000000e-08
GCST007321_6	Family history of Alzheimer’s disease	8.000000e-06
GCST009021_15	Alzheimer’s disease	5.000000e-09
GCST009391_1790	Metabolite levels	9.000000e-06
GCST012490_346	Femur bone mineral density x serum urate levels interaction	1.000000e-13
GCST90002387_284	Immature fraction of reticulocytes	9.000000e-37
GCST90002397_148	Mean spheric corpuscular volume	3.000000e-12
GCST90002404_262	Red cell distribution width	1.000000e-31
GCST90020028_598	Hip circumference adjusted for BMI	8.000000e-12

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004578	homocysteine measurement
EFO:0007986	reticulocyte count
EFO:0009188	Red cell distribution width
EFO:0009268	family history of Alzheimer’s disease
EFO:0004468	glucose measurement
EFO:0010477	fructose measurement
EFO:0010481	galactose measurement
EFO:0004531	urate measurement
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D005923	Glomerulosclerosis, Focal Segmental	C12.050.351.968.419.570.363.640; C12.200.777.419.570.363.660; C12.950.419.570.363.640
D007674	Kidney Diseases	C12.050.351.968.419; C12.200.777.419; C12.950.419
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5465369 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
perfluorooctane sulfonic acid	decreases expression	2
Acetaminophen	decreases expression	2
Arsenic	increases expression, affects methylation, increases abundance	2
Tobacco Smoke Pollution	affects expression, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
sodium arsenate	decreases expression	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	increases abundance, increases expression	1
cobaltous chloride	decreases expression	1
perfluorooctanoic acid	decreases expression	1
potassium chromate(VI)	decreases expression, affects cotreatment	1
epigallocatechin gallate	decreases expression, affects cotreatment	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
jinfukang	decreases expression	1
LDN 193189	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants, Occupational	affects expression	1
Caffeine	increases phosphorylation	1
Carbamazepine	affects expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	decreases phosphorylation	1
Ribonucleotides	affects binding	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5338441	Binding	Binding affinity to Cd2ap (unknown origin) at 200 uM preincubated for 2 hrs followed by pronase addition and measured after 30 mins by coomassie blue staining based SDS-PAGE gel analysis	Structurally Diverse Alkaloids with Anti-Renal-Fibrosis Activity from the Centipede Scolopendra subspinipes mutilans. — J Nat Prod

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01129557	PHASE4	TERMINATED	Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
NCT02399462	PHASE4	WITHDRAWN	Acthar for Treatment of Post-transplant FSGS
NCT02585804	PHASE4	COMPLETED	Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
NCT02633046	PHASE4	COMPLETED	Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
NCT07219121	PHASE4	RECRUITING	Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer